(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
Showing 11 - 16 of 16 records.
This phase I trial studies the side effects and best dose of lenalidomide when given together with monoclonal antibody with or without isotretinoin in treating younger patients with refractory or recurrent neuroblastoma. Drugs used in chemotherapy, such as lenalidomide and isotretinoin, work in dif...More
This Phase II study is designed to compare the response rates (RR) and progression free survival (PFS) for patients with refractory, relapsed or progressive neuroblastoma receiving temsirolimus or ch14.18 in combination with irinotecan and temozolomide....More
This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth....More
This phase I trial studies the side effects and the best dose of crizotinib giving together with combination chemotherapy in treating younger patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma. Crizotinib may stop the growth of tumor or cancer cells by blocking some...More
study will combine an oral drug called DFMO with celecoxib (also oral) and two
IV chemotherapy medicines called cyclophosphamide and topotecan. To find the highest dose of DFMO that can be given with
celecoxib, cyclophosphamide and topotecan without causing severe side effects.To find out ...More
This phase I/II trial studies the side effects
and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in
treating younger patients with solid tumors that have come back or that have
not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan
hydrochloride may stop the...More
Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at email@example.com or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.
The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center